Drug Profile
Furmonertinib - Allist Pharmaceuticals/ArriVent Biopharma
Alternative Names: Alflutinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma; AST-2818; Furmonertinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma; Iflutinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma; Ivesa; Vometinib mesylate - Allist Pharmaceuticals/ArriVent BiopharmaLatest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator Allist Pharmaceuticals
- Developer Allist Pharmaceuticals; ArriVent Biopharma
- Class Amides; Antineoplastics; Diamines; Fluorinated hydrocarbons; Indoles; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
Most Recent Events
- 30 Oct 2023 Furmonertinib - Allist Pharmaceuticals/ArriVent Biopharma receives Breakthrough Therapy status for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in USA
- 09 Sep 2023 Efficacy data from a phase Ib trial in Non small cell lung cancer presented at the 24th World Conference on Lung Cancer (WCLC-2023)
- 01 Jun 2023 Phase-III clinical trials in Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in Israel, Brazil (PO) (NCT05607550)